LOQTORZI
LOQTORZI (toripalimab-tpzi) is a programmed death receptor-1 (PD-1) blocking antibody indicated for the treatment of adult patients with nasopharyngeal carcinoma (NPC). It is used as a first-line treatment for metastatic or recurrent locally advanced NPC when administered in combination with cisplatin and gemcitabine. The drug is also indicated as a single agent for patients with recurrent unresectable or metastatic NPC whose disease has progressed on or after platinum-containing chemotherapy.
How LOQTORZI Works
Toripalimab-tpzi is a humanized IgG4 monoclonal antibody that binds to the PD-1 receptor on T cells. This binding blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often used by tumors to inhibit T cell proliferation and immune surveillance. By preventing this interaction, the drug releases the inhibition of the immune response, thereby enhancing the body's anti-tumor activity.
Details
- Status
- Prescription
- First Approved
- 2023-10-27
- Routes
- INJECTION
- Dosage Forms
- INJECTABLE
LOQTORZI Approval History
What LOQTORZI Treats
1 indicationsLOQTORZI is approved for 1 conditions since its original approval in 2023. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Nasopharyngeal Carcinoma
LOQTORZI Target & Pathway
ProTarget
An immune checkpoint receptor on T-cells that acts as an 'off switch' for immune responses. Cancer cells often exploit PD-1 by expressing its ligands (PD-L1/PD-L2), allowing tumors to evade immune detection. Blocking PD-1 releases this brake, enabling T-cells to recognize and attack cancer cells.
Pathway Context
PD-1 on T-cells binds to PD-L1/PD-L2 on tumor cells, suppressing immune attack
A protein expressed on tumor cells and immune cells that binds to PD-1 on T-cells, suppressing immune responses. Many cancers overexpress PD-L1 to avoid immune attack. Blocking PD-L1 prevents this immune suppression, allowing the body's T-cells to fight cancer.
A second ligand for PD-1, expressed on antigen-presenting cells and some tumors. PD-L2 binds PD-1 with higher affinity than PD-L1 but is less widely expressed. Drugs blocking PD-1 prevent both PD-L1 and PD-L2 interactions.
LOQTORZI Competitors
Pro10 other drugs also target PD-1. Compare mechanisms, indications, and trial activity.
Competitors share the same molecular target (PD-1). Earlier expiry dates signal biosimilar/generic opportunities.
Drugs Similar to LOQTORZI
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
LOQTORZI FDA Label Details
ProIndications & Usage
FDA Label (PDF)LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy 1.1 First-line Treatment of Metastatic or Recurrent, Locally Advanced NPC with Cisplatin and Gemcitabine LOQTORZI is indicated, in combination with cisplatin and gemcitabine, for the first-line...
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.